EPHA2 and neoplasm: However, loss or decrease of antigen in tumor cells has become the main obstacles for EGFRvIII’s further study [32], and overlapping of the antigen expression on normal tissues has caused off-target side-effects in patients receiving CAR-T cells targeting IL13Rα2 [40] and EphA2 [41].